H1B Report
Side-by-side comparison

KBI Biopharma, Inc. vs Microsoft Corporation

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
KBI Biopharma, Inc.
NCRank #FEIN 80-0058312
Entity B
Microsoft Corporation
WARank #5FEIN 91-1144442

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricKBI Biopharma, Inc.Microsoft Corporation
Total filings11472,912
Certified %90.35%94.30%
Denied %3.51%0.15%
Withdrawn %1.75%0.69%
Cert-withdrawn %4.39%4.85%
Rank#5
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNCWA

Outcomes — KBI Biopharma, Inc.

DOL case-status mix.

Outcome breakdown: Certified 90.3%, Cert-withdrawn 4.4%, Withdrawn 1.8%, Denied 3.5%
Outcome breakdown
OutcomeShare
Certified90.3%
Cert-withdrawn4.4%
Withdrawn1.8%
Denied3.5%
Certified90.3%
Cert-withdrawn4.4%
Withdrawn1.8%
Denied3.5%

Outcomes — Microsoft Corporation

DOL case-status mix.

Outcome breakdown: Certified 94.3%, Cert-withdrawn 4.9%, Withdrawn 0.7%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

KBI Biopharma, Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102
FY20114
FY20122
FY20132
FY201410
FY20154
FY20166
FY201710
FY20185
FY201911
FY20201
FY20210
FY20222
FY20236
FY202411
FY202528
FY202610
Microsoft Corporation
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20104,407
FY20114,184
FY20124,005
FY20133,832
FY20143,674
FY20154,476
FY20164,919
FY20174,884
FY20185,457
FY20196,000
FY202051
FY2021110
FY2022150
FY20232,791
FY20249,492
FY20259,362
FY20265,118

Top 5 occupations — KBI Biopharma, Inc.

Top 5 occupations — Microsoft Corporation

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.